Short answer
Immunovant, Inc. (IMVT) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Fiscal Q2 and six months ended September 30, 2026 financial results announced.
Immunovant, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Fiscal Q2 and six months ended September 30, 2026 financial results announced
- Press release dated November 9, 2026 contains the results and accompanying management disclosures
- Exhibit 99.1 provides the substantive financial details for investor review
Item EX-99.1 · Exhibit EX-99.1
- IMVT-1402 600 mg met primary ACR20 endpoint in D2T RA: 92.5% vs 75.6% placebo, p=0.0139
- Dose differentiation emerged: 300 mg showed no placebo advantage, with 75.0% ACR20 response, p=0.9426
- FDA discussions planned later in 2026 to determine the D2T RA registrational path
- Sjögren’s development likely stops after the ongoing Phase 2 trial, narrowing IMVT-1402’s opportunity set
- Cash $722.3M supports planned operations through potential GD launch, while Q2 net loss reached $97.2M or $0.47 per share
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Immunovant, Inc. 8-K filings
Get the next IMVT 8-K as it lands
Follow IMVT for push alerts, or ask the research agent what this filing means.